Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
The pheochromocytomas are an important cause of secondary hypertension. Although pheochromocytoma susceptibility may be associated with germline mutations in the tumor-suppressor genes VHL and NF1 and in the proto-oncogene RET, the genetic basis for most cases of nonsyndromic familial pheochromocytoma is unknown. Recently, pheochromocytoma susceptibility has been associated with germline SDHD mutations. Germline SDHD mutations were originally described in hereditary paraganglioma, a dominantly inherited disorder characterized by vascular tumors in the head and the neck, most frequently at the carotid bifurcation. The gene products of two components of succinate dehydrogenase, SDHC and SDHD, anchor the gene products of two other components, SDHA and SDHB, which form the catalytic core, to the inner-mitochondrial membrane. Although mutations in SDHC and in SDHD may cause hereditary paraganglioma, germline SDHA mutations are associated with juvenile encephalopathy, and the phenotypic consequences of SDHB mutations have not been defined. To investigate the genetic causes of pheochromocytoma, we analyzed SDHB and SDHC, in familial and in sporadic cases. Inactivating SDHB mutations were detected in two of the five kindreds with familial pheochromocytoma, two of the three kindreds with pheochromocytoma and paraganglioma susceptibility, and 1 of the 24 cases of sporadic pheochromocytoma. These findings extend the link between mitochondrial dysfunction and tumorigenesis and suggest that germline SDHB mutations are an important cause of pheochromocytoma susceptibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“germline mutations in the B, C and D subunits of SDH predispose individuals to hereditary paragangliomatosis with phaeochromocytomas (HPGL) (2 -6)”
From Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations (2005) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, a biallelic loss of succinate dehydrogenase (SDH), an alteration found in familial paragangliomas and pheochromocytomas, as well as in a subset of sporadic gastrointestinal stromal tumors, creates a build-up of succinate (Astuti et al., 2001; Janeway et al., 2011).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Astuti et al., 2001
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The results of a clinical study further confirmed this observation by showing that patients with nonmetastatic lung cancer harbored loss-of-function mutations in SDH5128.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [128]
Experimental — accuracy not yet measuredIn the citing paper
“In cancer cells, mutations in succinate dehydrogenase subunit B (SDHB) cause susceptibility to familial pheochromocytoma99 and familial paraganglioma100 as well as gastrointestinal stromal tumors101.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [99]
In the citing paper
“In addition to the tumorigenic effects of succinate accumulation, SDH5 mutation is the key driver supporting the acquisition of epithelial–mesenchymal transition (EMT) characteristics.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [128]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 2×
“…cancers and in mouse models, results in up-regulation of angiogenic growth factors, such as vascular endothelial growth factor, secondary to a defect in ubiquitylation of the a-subunits of the HIF-1 and the HIF-2 transcription factors (Maxwell et al. 1999; Cockman et al. 2000; Ohh et al. 2000).”
BackgroundSelf-citationMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 3×
“…the iron-sulfur–protein subunit) and in both SDHC and SDHD (i.e., the genes for the integral membrane–protein subunits) are associated with neoplasia (Baysal et al. 2000; Niemann and Muller 2000; present study), autosomal recessive homozygous SDHA (i.e., the gene for the flavoprotein subunit)…”
BackgroundOhh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577 · cited 2×
“…cancers and in mouse models, results in up-regulation of angiogenic growth factors, such as vascular endothelial growth factor, secondary to a defect in ubiquitylation of the a-subunits of the HIF-1 and the HIF-2 transcription factors (Maxwell et al. 1999; Cockman et al. 2000; Ohh et al. 2000).”
BackgroundCockman, M. E., Masson, N., Mole, D. R., Jaakkola, P., Chang, G.-W., Clifford, S. C., Maher, E. R., Pugh, C. W., Ratcliffe, P. J., & Maxwell, P. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002740200 · Cited by 1,050 · cited 1×
“…cancers and in mouse models, results in up-regulation of angiogenic growth factors, such as vascular endothelial growth factor, secondary to a defect in ubiquitylation of the a-subunits of the HIF-1 and the HIF-2 transcription factors (Maxwell et al. 1999; Cockman et al. 2000; Ohh et al. 2000).”
BackgroundSelf-citationMutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875 · cited 4×
“…herein: PGL1 (MIM 168000), which results from SDHD mutations at 11q23; PGL2 (MIM 601650), which maps to 11q13, although the causative gene has not been identified (Mariman et al. 1995); and PGL3 (MIM 605373), which results from SDHC mutations at 1q21 (Baysal et al. 2000; Niemann and Muller 2000).”
BackgroundInfluentialBourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., Viegas-Péquignot, E., Munnich, A., & Rötig, A. (1995) · Nature Genetics · doi:10.1038/ng1095-144 · Cited by 730 · cited 2×
“SDHA mutations are associated with juvenile encephalopathy (Bourgeron et al. 1995), and the phenotypic consequences of SDHB mutations have not been defined.”
BackgroundHoffman, M. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1019 · Cited by 382 · cited 1×
“Interestingly, germline VHL mutations that predispose patients to pheochromocytoma do not impair HIF-1a ubiquitylation (Clifford et al. 2001; Hoffman et al. 2001).”
BackgroundClifford, S. C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1029 · Cited by 373
Gimm, O., Armanios, M. Y., Dziema, H., Neumann, H. P. H., & Eng, C. (2000) · PubMed · Cited by 274
Self-citation
Cited by
Items 601–700 of 999
Waldmann, J., Langer, P., Habbe, N., Fendrich, V., Ramaswamy, A., Rothmund, Μ., Bartsch, D. K., & Slater, E. P. (2009) · Endocrine · doi:10.1007/s12020-009-9178-y · Cited by 21
“Germ line mutations in the SDHB and SDHD gene were not detected which is consistent with the low frequency in these genes of approximately 4% (4–22) [1, 2, 6, 13].”
BackgroundResultInfluentialPelizzo, M. R., Conti, C., Pennelli, G., Bellan, E., Cook, G., Wong, K. K., Colletti, P. M., Boschin, I. M., & Rubello, D. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000295 · Cited by 20
“Hereditary PGs generally present with mutations of the succinate dehydrogenase (SDH) (SDH-B, SDH-C, and SDH-D) genes, which can also be found in sporadic tumors.(3,5,6) A search for other synchronous or metachronous tumors is therefore mandatory in these patients with imaging and hormonal activity assessment, and cons…”
BackgroundHoekstra, A. S., Addie, R. D., Ras, C., Seifar, R. M., Ruivenkamp, C. A. L., Bruijn, I. H. B., Hes, F. J., Jansen, J. C., Corssmit, E. P. M., Corver, W. E., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw218 · Cited by 22
Anyfanti, P., Mastrogiannis, Κ., Lazaridis, A. A., Tasios, Κ., Vasilakou, D., Kyriazidou, Α., Aroutsidis, F., Pavlidou, O., Papoutsopoulou, Ε., Tiritidou, A., et al. (2022) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2022.2132012 · Cited by 21
Ketogenic diet as a treatment and prevention strategy for cancer: A therapeutic alternative
Neha, N., & Chaudhary, R. (2024) · Nutrition · doi:10.1016/j.nut.2024.112427 · Cited by 23
Selenoprotein O Promotes Melanoma Metastasis and Regulates Mitochondrial Complex II Activity
Melo, L. M. N., Sabatier, M., Ramesh, V., Szylo, K. J., Fraser, C. S., Pon, A., Mitchell, E. C., Servage, K. A., Allies, G., Westedt, I. V., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2194 · Cited by 21
“Mutations in the genes encoding succinate dehydrogenase subunits have been associated with hereditary paraganglioma–pheochromocytoma syndrome and some sporadic cancers (44–46).”
Paepe, B. D. (2012) · ISRN Pathology · doi:10.5402/2012/217162 · Cited by 23
“SDHB mutations have also been shown in pheochromocytoma [92] and renal cell carcinomas [93].”
BackgroundMitochondrial and Nuclear Genes of Mitochondrial Components in Cancer
Kirches, E. (2009) · Current Genomics · doi:10.2174/138920209788488517 · Cited by 21
“SDHB mutations were found in two of the five families screened and the same gene was occasionally affected in sporadic forms of the disease [45].”
BackgroundPheochromocytoma/Paraganglioma: Is This a Genetic Disorder?
Fishbein, L. M. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1184-y · Cited by 22
SDHB mutation analysis in familial and sporadic phaeochromocytoma identifies a novel mutation
Cascón, A., Cebrián, A., Ruiz-Llorente, S., Tellería, D., Benítez, J., & Robledo, M. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.10.e64 · Cited by 20
Papaspyrou, K., Rossmann, H., Fottner, C., Weber, M. M., Mann, W. J., Lackner, K. J., & Helling, K. (2008) · Head & Neck · doi:10.1002/hed.20746 · Cited by 19
“All exons and splice sites of the SDH subunit genes SDHB, SDHC, and SDHD were amplified from genomic DNA (isolated from whole blood, High Pure PCR template preparation kit, Roche Diagnostics, Mannheim, Germany) using published primers and polymerase chain reaction (PCR) conditions.(1,6,8,11) No mutations were detected…”
MethodRaygada, M. J., King, K. S., Adams, K. T., Stratakis, C. A., & Pacák, K. (2014) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2013-0369 · Cited by 23
Pheochromocytomas and Paragangliomas—Current Management
Brewczyński, A., Kolasińska, A. D., Jabłońska, B., & Wyrwicz, L. S. (2025) · Cancers · doi:10.3390/cancers17061029 · Cited by 22
“Abnormal laboratory results (increased metanephrine and catecholamine secretion) or neck tumors are common indications for radiological diagnostics [11,21,63,65–68].”
Ricketts, C. J., Killian, J. K., Vocke, C. D., Wang, Y., Merino, M. J., Meltzer, P. S., & Linehan, W. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0278108 · Cited by 20
Metabolic Alterations at the Crossroad of Aging and Oncogenesis
Raffaghello, L., & Longo, V. D. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.01.003 · Cited by 20
“, 2011), which have been found mutated in patients affected by different malignancies including hereditary paragangliomas, pheochromocytomas, gastrointestinal stromal, thyroid and renal tumors, neuroblastoma, and testicular seminoma (Astuti et al., 2001; Bardella et al., 2011; Baysal et al., 2000).”
BackgroundControl of topoisomerase II activity and chemotherapeutic inhibition by TCA cycle metabolites
Lee, J. H., Mosher, E. P., Lee, Y., Bumpus, N. N., & Berger, J. M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.08.014 · Cited by 18
Zhao, Z., Rothery, R. A., & Weiner, J. H. (2006) · Biochemistry and Cell Biology · doi:10.1139/o06-188 · Cited by 18
“It was initially proposed that PGL tumor formation might be associated with superoxide (one of the so-called reactive oxygen species (ROS)) overproduction by Sdh caused by the mutations (Astuti et al. 2001; Rustin et al. 2002; Rustin and Rotig 2002).”
BackgroundFrom Transcriptional Profiling to Tumor Biology in Pheochromocytoma and Paraganglioma
Cascón, A., & Tennant, D. A. (2012) · Endocrine Pathology · doi:10.1007/s12022-012-9195-x · Cited by 17
Martinelli, S., Riverso, M., Mello, T., Amore, F., Parri, M., Simeone, I., Mannelli, M., Maggi, M., & Rapizzi, E. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111594 · Cited by 19
“Indeed, more than 20 genes are responsible for a hereditary background in up to 40% of these tumours (Astuti et al., 2001; Baysal et al., 2000; Buffet et al., 2018; Burnichon et al., 2010; Calsina et al., 2018; Castro-Vega et al., 2014; Comino-Méndez et al., 2011; Crona et al., 2013; Dwight et…”
BackgroundFunctional Consequences of Succinate Dehydrogenase Mutations
Opocher, G., & Schiavi, F. (2011) · Endocrine Practice · doi:10.4158/ep11070.ra · Cited by 18
Venkatesan, A. M., Trivedi, H., Adams, K. T., Kebebew, E., Pacák, K., & Hughes, M. S. (2011) · Surgery · doi:10.1016/j.surg.2011.09.026 · Cited by 19
A Giant Cystic Pheochromocytoma of the Adrenal Gland
Pan, Z., Repertinger, S. K., Deng, C., & Sharma, P. (2008) · Endocrine Pathology · doi:10.1007/s12022-008-9016-4 · Cited by 17
“Recently, mutations of the SDHD and SDHB genes were identified in familial paragangliomas [9, 10].”
BackgroundMontani, M., Schmitt, A. M., Schmid, S., Locher, T., Saremaslani, P., Heitz, P. U., Komminoth, P., & Perren, A. A. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00996 · Cited by 17
“Mutations of the tumor suppressor genes SDHD (Baysal et al. 2000), SDHC (Niemann & Muller 2000) and SDHB ( Astuti et al. 2001 ) have recently been described in familial paragangliomas and pheochromocytomas.”
BackgroundBayley, J., Weiss, M. M., Grimbergen, A., van Brussel, B. T. J., Hes, F. J., Jansen, J. C., Verhoef, S., Devilee, P., Corssmit, E. P. M., & Vriends, A. H. J. T. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0084 · Cited by 19
“Further subunits of SDH were subsequently shown to be involved in both head and neck paragangliomas and pheochromocytoma (Niemann & Muller 2000, Astuti et al .”
BackgroundAlterations of respiratory chain complexes in sporadic pheochromocytoma
Kofler, B. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e233 · Cited by 19
“, who also did not find an association of sporadic PC with SDHB inactivation (25-27).”
BackgroundPast, Present and Future of Human Chromaffin Cells: Role in Physiology and Therapeutics
Pérez‐Alvarez, A., Hernández‐Vivanco, A., & Albillos, A. (2010) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-010-9582-0 · Cited by 19
“Two other genes related to familial paraganglioma, SDHB and SDHD, encode subunits of SDH, the enzyme that composes mitochondrial complex II (Astuti et al. 2001; Baysal et al. 2000).”
BackgroundCasting an eye on the Krebs cycle
Münnich, A. (2008) · Nature Genetics · doi:10.1038/ng1008-1148 · Cited by 20
Novel ways to target brain tumour metabolism
Stieber, D., Rahim, S. A. A., & Niclou, S. P. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.588211 · Cited by 17
“In hereditary head and neck paragangliomas for instance, mutations in the gene coding for succinate dehydrogenase, involved in the mitochondrial respiratory chain complex II, leads to an accumulation of succinate, which stabilizes steady state levels of HIF1a by inhibiting HIF prolyl hydroxylases [55,56].”
BackgroundBaqader, N. O., Radulović, M., Crawford, M., Stoeber, K., & Godovac‐Zimmermann, J. (2014) · Journal of Proteome Research · doi:10.1021/pr500638h · Cited by 16
Fumarate Metabolic Signature for the Detection of Reed Syndrome in Humans
Casey, R. T., McLean, M. A., Challis, B., McVeigh, T. P., Warren, A. Y., Mendil, L., Houghton, R., de Sanctis, S., Kosmoliaptsis, V., Sandford, R. N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1729 · Cited by 16
“org Clin Cancer Res; 26(2) January 15, 2020 395”
BackgroundInfluentialSelf-citationMouse Models of Human Familial Paraganglioma
Maher, L. J., III, Emily, H., Emily, M., Nicole, A., Paul, J., Nelson-Holte, M. H., Piruat, J. I., García‐Flores, P., López‐Barneo, J., & van, J. (2011) · InTech eBooks · doi:10.5772/25346 · Cited by 21
Novel Hereditary Forms of Pheochromocytomas and Paragangliomas
Dahia, P. L. M. (2013) · Frontiers of hormone research · doi:10.1159/000345671 · Cited by 18
Self-citationUpdate on the Molecular Diagnosis of Endocrine Tumors: Toward –omics-Based Personalized Healthcare?
Weber, F., & Eng, C. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0212 · Cited by 16
Self-citationDiagnosis of silent pheochromocytoma and paraganglioma
Clifton-Bligh, R. J. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.76 · Cited by 17
Ishii, T., Yasuda, K., Miyazawa, M., Mitsushita, J., Johnson, T. E., Hartman, P. S., & Ishii, N. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.02.013 · Cited by 16
“SDHB, SDHC and SDHD heterozygous mutations cause a genetic predisposition to non-chromaffin palagamgliomas (PGLs) and adrenal ⁄extra-adrenal phaeochromocytomas (PHEOs) called ‘PGL/PHEO syndrome’ (Baysal et al., 2000; Niemann et al., 2000; Astuti et al., 2001).”
BackgroundMitochondrial complex II regulates a distinct oxygen sensing mechanism in monocytes
Sharma, S., Wang, J., Gomez, E. C., Taggart, R. T., & Baysal, B. E. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx041 · Cited by 16
Zhu, W. D., Wang, Z. Y., Chai, Y., Wang, X. W., Chen, D. Y., & Wu, H. (2015) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2015.05.008 · Cited by 16
Bausch, B., Boedeker, C. C., Berlis, A., Brink, I., Cybulla, M., Walz, M. K., Januszewicz, A., Letizia, C., Opocher, G., Eng, C., et al. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.013 · Cited by 18
Self-citationAn Examination of Chimpanzee Use in Human Cancer Research
Bailey, J. (2009) · Alternatives to Laboratory Animals · doi:10.1177/026119290903700410 · Cited by 17
A rare case of Cushing syndrome by cyclic ectopic-ACTH
Farage, M., Costa, M. A. D. D. L., & Godoy‐Matos, A. F. (2012) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302012000500008 · Cited by 15
“Heterozygous mutations of the last three subunits have been associated with a genetic predisposition to HNPGLs and adrenal/extra-adrenal pheochromocytomas (PHEOs) (15,16).”
BackgroundChoat, H. M., Derrevere, K., Knight, L., Brown, W., & Mack, E. H. (2014) · Case Reports in Endocrinology · doi:10.1155/2014/502734 · Cited by 15
“While SDH subunit gene mutations have been shown to be associated with neoplasia and cause susceptibility to familial PCC/ PGL syndromes, an exact causal mechanism is still unclear [20].”
BackgroundNovel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome
Patócs, A., Lendvai, N. K., Butz, H., Likó, I., Sápi, Z., Szücs, N., Tóth, G., Grolmusz, V. K., Igaz, P., Tóth, M., et al. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0050-0 · Cited by 18
Lee, S. E., Oh, E., Lee, B., Kim, Y. J., Oh, D., Jung, K., Choi, J., Kim, J., Kim, S. J., Yang, J. W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8234 · Cited by 15
“Mutations of the succinate dehydrogenase subunit B gene (SDHB) were associated with high rates of malignancy and extraadrenal tumor metastasis [7, 8].”
BackgroundLi, C., Liu, C.-Q., Zhang, H., Chen, C.-P., Yang, X., Chen, L., Liu, Q., Guo, J., Sun, C., Wang, P., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010157 · Cited by 15
Mitochondrial substrates in cancer: Drivers or passengers?
Kruspig, B., Zhivotovsky, B., & Gogvadze, V. G. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.08.007 · Cited by 15
Genetic and clinical characteristics of head and neck paragangliomas in a chinese population
Zheng, X., Wei, S., Yu, Y., Xia, T., Zhao, J., Gao, S., Li, Y., & Gao, M. (2012) · The Laryngoscope · doi:10.1002/lary.23360 · Cited by 15
“Genetic screenings have revealed that about 30% of PGLs are caused by hereditary mutations.(5) The predisposing genes that have been identified seem at first glance to have entirely different functions, but in spite of this, malfunction of their different gene products can give rise to clinically and histologically un…”
BackgroundParagangliomas Arising in the Head and Neck
Williams, M. D., & Rich, T. A. (2014) · Surgical pathology clinics · doi:10.1016/j.path.2014.08.007 · Cited by 15
Else, T. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0221 · Cited by 17
Radiologist’s Primer on Imaging of Common Hereditary Cancer Syndromes
Tiwari, R., Singh, A. K., Somwaru, A. S., Menias, C. O., Prasad, S. R., & Katabathina, V. S. (2019) · Radiographics · doi:10.1148/rg.2019180171 · Cited by 17
Sporadic paraganglioma caused by de novo SDHB mutations in a 6-year-old girl
Imamura, H., Muroya, K., Tanaka, E., Konomoto, T., Moritake, H., SATO, T. A., Kimura, N., Takekoshi, K., & Nunoi, H. (2015) · European Journal of Pediatrics · doi:10.1007/s00431-015-2614-5 · Cited by 17
“In some previously evaluated cases, simple LOH analysis or allelic imbalance showed somatic deletion of the wild-type allele; however, it is present in only 60 % of SDHB-related tumors [1, 8, 15].”
BackgroundHensen, E. F., Goeman, J. J., Oosting, J., van der Meij, A. G. L., Hogendoorn, P. C. W., Cremers, C. W. R. J., Devilee, P., & Cornelisse, C. J. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-25 · Cited by 17
“Mutations in SDHB, SDHC and SDHD are also implicated in the formation of phaeochromocytomas, tumors arising in cells derived from the neural crest in the adrenal medulla [6-8].”
Novel Germline Mutations in the SDHB and SDHD Genes in Japanese Pheochromocytomas
Isobe, K., Minowada, S., Tatsuno, I., Suzukawa, K., Nissato, S., Nanmoku, T., Hara, H., YASHIRO, T., Kawakami, Y., & Takekoshi, K. (2007) · Hormone Research in Paediatrics · doi:10.1159/000099655 · Cited by 16
Eng, C. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn263 · Cited by 16
Self-citationPheochromocytoma: When to search a germline defect?
Buffet, A., Burnichon, N., Amar, L., & Gimenez‐Roqueplo, A. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.07.003 · Cited by 14
Model systems in SDHx-related pheochromocytoma/paraganglioma
Takács‐Vellai, K., Farkas, Z., Ősz, F., & Stewart, G. W. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-10009-z · Cited by 16
Kodama, H., Iihara, M., Nissato, S., Isobe, K., Kawakami, Y., Okamoto, T., & Takekoshi, K. (2010) · Endocrine Journal · doi:10.1507/endocrj.k09e-324 · Cited by 14
Bennedbæk, M., Rossing, M., Rasmussen, Å. K., Gerdes, A., Skytte, A., Jensen, U. B., Nielsen, F. C., & Hansen, T. V. O. (2016) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-016-0053-6 · Cited by 16
“protein 127 (TMEM127), MYC-associated factor X (MAX), fumarate hydratase (FH), and succinate dehydrogenase complex subunit A, B, C, D, and AF2 (SDHA, SDHB, SDHC, SDHD, SDHAF2) [3–13].”
Etiopathogenesis of oncocytomas
Correia, M., Silva-Pinheiro, P., Batısta, R., Soares, P., Sobrinho-Simões, M. A., & Máximo, V. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.014 · Cited by 17
Therapies targeting the signal pathways of pheochromocytoma and paraganglioma
Liu, Y., Liu, L., & Zhu, F. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s219056 · Cited by 14
“The discovery of SDH complex assembly in 2009 involved two factors, SDHAF1 and SDHAF2, which may play a part in the development of cancers related to this pathway.47,48 SDHA gene acts as tumor suppressor and is considered as a new PCC/PGL susceptibility gene.49 SDHB mutations and SDHC mutations were also proven to hav…”
BackgroundAnttila, T., Häyry, V., Nicoli, T., Hagström, J., Aittomäki, K., Vikatmaa, P., Niemela, M. R., Saarilahti, K., Mäkitie, A. A., & Bäck, L. J. J. (2014) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-014-3161-9 · Cited by 14
15 YEARS OF PARAGANGLIOMA: Metabolism and pheochromocytoma/paraganglioma
Mannelli, M., Rapizzi, E., Fucci, R., Canu, L., Ercolino, T., Luconi, M., & Young, W. F. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0215 · Cited by 15
68Ga-DOTATATE PET–CT imaging in carotid body paragangliomas
Şimşek, D. H., Şanlı, Y., Kuyumcu, S., Başaran, B., & Mudun, A. (2018) · Annals of Nuclear Medicine · doi:10.1007/s12149-018-1242-3 · Cited by 14
Velasco, A., Palomar-Asenjo, V., Ga??an, L., Catasús, L., Llecha, N., Panizo, Á., Palomar-Garcia, V., Quer, M., & Matías‐Guiu, X. (2005) · Diagnostic Molecular Pathology · doi:10.1097/01.pas.0000158987.07907.7e · Cited by 16
“A few SDHB mutations have been reported, and they have been found in small families with only two or three affected patients.(4) It has been suggested that SDHB mutations may be associated with poorer phenotypic fitness.”
BackgroundA case of familial paraganglioma syndrome type 4 caused by a mutation in the SDHB gene
Drucker, A. M., & Houlden, R. L. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0342 · Cited by 14
Experience with Surgical Excision in Childhood Pheochromocytoma
Kim, H., Lee, H. S., Jung, S. E., Lee, S., Park, K., & Kim, W. (2004) · Journal of Korean Medical Science · doi:10.3346/jkms.2004.19.3.401 · Cited by 16
“Succinate dehydrogenase mutation has been described previously in five families with familial paraganglioma syndrome (25-27).”
BackgroundManotas, M. C., Rivera-Herrera, A.-L., Gómez, A. M., Abisambra, P., Guevara, G., Medina, V., Tapiero, S., Huertas, A., Riaño-Moreno, J. C., Mejía, J. C., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.999329 · Cited by 12
“SDHB acts as a tumor suppressor gene associated as a cause of hereditary PPGL (Astuti et al., 2001).”
BackgroundCrona, J., Ljungström, V., Welin, S., Walz, M. K., Hellman, P., & Björklund, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133210 · Cited by 16
Genetics of pheochromocytoma and paraganglioma: New developments
Pigny, P., & Cardot-Bauters, C. (2009) · Annales d Endocrinologie · doi:10.1016/j.ando.2009.11.004 · Cited by 14
“In 2001 [8], mutations of DHB were found in patients with hereditary PGL or pheochroocytoma, leading to the identification of a fourth loci, i.”
BackgroundBarber, B. R., Ingram, M. D., Khan, S., Bano, G., Hodgson, S. V., & Vlahos, I. (2011) · Insights into Imaging · doi:10.1007/s13244-011-0096-1 · Cited by 13
“Subsequent studies confirmed that SDHB and SDHC mutations also resulted in familial paragangliomas [10, 11].”
BackgroundMetabolomics in the Diagnosis of Pheochromocytoma and Paraganglioma
Dwight, T., Kim, E., Novos, T., & Clifton-Bligh, R. J. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0926-3790 · Cited by 16
Lawrence, J., Maher, E. R., Sheaves, R., & Grossman, A. B. (2004) · HORMONES · doi:10.14310/horm.2002.11121 · Cited by 13
Self-citationPreferential MGMT hypermethylation in SDH-deficient wild-type GIST
Giger, O., ten Hoopen, R., Shorthouse, D., Abdullahi, S., Bulusu, V. R., Jadhav, S., Maher, E. R., & Casey, R. T. (2022) · Journal of Clinical Pathology · doi:10.1136/jcp-2022-208462 · Cited by 14
Self-citationGermline predisposition in multiple myeloma
Rodrigues, F. M., Jasielec, J. K., Perpich, M., Kim, A., Moma, L., Li, Y., Storrs, E. P., Wendl, M. C., Jayasinghe, R. G., Fiala, M. A., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111620 · Cited by 12
Rubinstein, W. S. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.06.008 · Cited by 15
Translational Research in Endocrine Surgery
Sherman, S. K., & Howe, J. R. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.012 · Cited by 12
Contiguous bilateral head and neck paragangliomas in a carrier of the SDHB germline mutation
Collins, N., & Dietzek, A. M. (2011) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2011.06.084 · Cited by 12
No difference in phenotype of the main D utch SDHD founder mutations
van Hulsteijn, L. T., den Dulk, A. C., Hes, F. J., Bayley, J., Jansen, J. C., & Corssmit, E. P. M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12223 · Cited by 12
Hereditary Paraganglioma of the Nasopharynx
Said-Al-Naief, N. A. H., & Ojha, J. (2008) · Head and Neck Pathology · doi:10.1007/s12105-008-0090-1 · Cited by 12
Laiho, P., Hienonen, T., Mecklin, J.-P., Järvinen, H., Karhu, A., Launonen, V., & Aaltonen, L. A. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.5.e73 · Cited by 12
Sir Hans Adolf Krebs: Architect of Metabolic Cycles
Wilson, B. A., Schisler, J. C., & Willis, M. S. (2010) · Laboratory Medicine · doi:10.1309/lmz5zlac85gfmghu · Cited by 15
Surveillance of succinate dehydrogenase gene mutation carriers: Insights from a nationwide cohort
Martins, R. G., Cunha, N., Simões, H., Matos, M. J., Silva, J., Torres, I., Rodrigues, F., Leite, V. A. P. H., Teixeira, M. R., & Bugalho, M. J. (2020) · Clinical Endocrinology · doi:10.1111/cen.14184 · Cited by 14
Aim, L. B., Maher, E. R., Cascón, A., Barlier, A., Giraud, S., Ercolino, T., Pigny, P., Clifton-Bligh, R. J., Mirebeau‐Prunier, D., Mohamed, A., et al. (2021) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2020-107652 · Cited by 12
Self-citationVayalil, P. K., Oh, J., Zhou, F., Diers, A. R., Smith, M. R., Golzarian, H., Oliver, P. G., Smith, R. A. J., Murphy, M. P., Velu, S. E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120460 · Cited by 15
“, pheochromocytoma, paraganglioma, familial renal cell carcinoma, glioma) [41–43].”
Multiple Catecholamine-Secreting Paragangliomas: Diagnosis after Hemorrhagic Stroke in a Young Woman
Petramala, L., Cavallaro, G., Polistena, A., Cotesta, D., Verrienti, A., Ciardi, A., Lucia, P., Filetti, S., D'Erasmo, E., Toma, G. D., et al. (2008) · Endocrine Practice · doi:10.4158/ep.14.3.340 · Cited by 12
Singh, D., Shukla, J., Walia, R., Vatsa, R., Paul, N., Chhabra, A., Nahar, U., Singh, H., Kumar, R., Bhansali, A. K., et al. (2020) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001251 · Cited by 13
Tackling Dysfunction of Mitochondrial Bioenergetics in the Brain
Zanfardino, P., Doccini, S., Santorelli, F. M., & Petruzzella, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158325 · Cited by 17
van Duinen, N., Kema, I. P., Romijn, J. A., & Corssmit, E. P. M. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03914.x · Cited by 13
Takekoshi, K., Isobe, K., Suzuki, H., Nissato, S., Kawakami, Y., Kawai, K., & Yamada, N. (2008) · Endocrine Journal · doi:10.1507/endocrj.k07-087 · Cited by 12
“found to be associated with the development of familial pheochromocytomas and paragangliomas (hereditary pheochromocytoma/paraganglioma syndrome: HPPS).”
BackgroundFamilial carotid body tumours: is there a role for genetic screening?
Jani, P., Qureshi, A. A., Verma, S., & Walker, L. (2007) · The Journal of Laryngology & Otology · doi:10.1017/s0022215107000023 · Cited by 13
Cascón, A., Cebrián, A., Pollán, M., Ruiz‐Llorente, S., Montero‐Conde, C., Letón, R., Gutiérrez, R. J., Lesueur, F., Milne, R. L., Albarrán, O. G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2059 · Cited by 12
Anaplerotic reactions in tumour proliferation and apoptosis
Quash, G., Fournet, G., & Reichert, U. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00106-0 · Cited by 12
Nan, H., Guo, P., Fan, J., Zeng, W., Hu, C., Zheng, C., Pan, B., Cao, Y. J., Ge, Y., Xue, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1093974 · Cited by 11
Breast Cancer Risk and Management in the Endocrine Clinic: A Comprehensive Review
Hawazie, A., & Druce, M. R. (2025) · Clinical Endocrinology · doi:10.1111/cen.15209 · Cited by 12
Analysis of SDHD promoter mutations in various types of melanoma
Scholz, S. L., Horn, S., Murali, R., Möller, I., Sucker, A., Sondermann, W., Stiller, M., Schilling, B., Livingstone, E., Zimmer, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4665 · Cited by 14
“Mutations in SDHD have been described in gastrointestinal stromal tumor (GIST) [19], paraganglioma [20, 21] and pheochromocytoma [22, 23].”
Shapiro, B. J., & Alm, E. J. (2009) · The ISME Journal · doi:10.1038/ismej.2009.51 · Cited by 10
An analysis of surveillance screening for SDHB-related disease in childhood and adolescence
Tufton, N., Shapiro, L., Sahdev, A., Kumar, A., Martin, L., Drake, W. M., Akker, S. A., & Storr, H. L. (2019) · Endocrine Connections · doi:10.1530/ec-18-0522 · Cited by 12
Martins, R. G., Gonçalves, L. G., Cunha, N., & Bugalho, M. J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01101 · Cited by 11
MAX mutations status in Swedish patients with pheochromocytoma and paraganglioma tumours
Crona, J., Maharjan, R., Verdugo, A. D., Stalberg, P. L. H., Granberg, D. O., Hellman, P., & Björklund, P. (2013) · Familial Cancer · doi:10.1007/s10689-013-9666-3 · Cited by 12
“Up to 60 % of the cases harbour germline or somatic mutations in one of eleven disease susceptibility genes [3–6]; SDH subunits A, B, C and D, SDHAF2, VHL, EPAS1, RET, NF1, TMEM127 and MYC associated factorX (MAX) [7–17].”
BackgroundRich, B. S., Moo, T.-A. S., Mark, S., Scognamiglio, T., Pecker, M. S., Sobol, I., LaRocca, G., & Fahey, T. J. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1969 · Cited by 12
Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism
Tevosian, S. G., & Ghayee, H. K. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01991 · Cited by 12
“ATRX Loss of function (13, 14) CSDE1 Loss of function (15) FH Loss of function (16) HIF2A Gain of function (17–19) HRAS Gain of function (20) IDH1 Gain of function (21) KIF1B Loss of function (22) MAML3 Gain of function (15) MAX Loss of function (23) MDH2 Loss of function (24) MEN2 (RET) Gain of function (25, 26) NF1…”
Background
Metadata
- Authors
- Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R.
- Affiliations
- University of Birmingham (GB)
- Dana-Farber Cancer Institute (US)
- Royal Victoria Infirmary (GB)
- Queen Elizabeth Hospital (GB)
- Uppsala University (SE)
- University of Cambridge (GB)
- Corresponding author
- Maher, Eamonn R.
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-07
- Volume
- 69
- Issue
- 1
- Pages
- 49-54
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1226047
- OpenAlex
- W2025719835
- Cited by
- 1,087
- References
- 28
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 18 · 2023: 31 · 2022: 29 · 2021: 40 · 2020: 29 · 2019: 51 · 2018: 42 · 2017: 47 · 2016: 54 · 2015: 46 · 2014: 70 · 2013: 61 · 2012: 75
- FWCI
- 37.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4401 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- British Heart Foundation
- National Cancer Institute (P-30-CA-16058, P30CA016058)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- succinate dehydrogenase, SDHB, SDHC, pheochromocytoma, paraganglioma, germline mutations, mitochondrial dysfunction, sporadic pheochromocytoma, tumor suppressor, RET proto-oncogene, VHL, neurofibromatosis type 1
- MeSH terms
- Proto-Oncogene Mas, Amino Acid Sequence, Base Sequence, DNA Mutational Analysis, Female, Haplotypes, Humans, Male, Molecular Sequence Data, Mutation, Paraganglioma, Pedigree, Pheochromocytoma, Succinate Dehydrogenase, Sequence Alignment, Germ-Line Mutation, Loss of Heterozygosity, Genetic Predisposition to Disease, Mutation, Missense, Protein Subunits
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.